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Abstract. Transient receptor potential vanilloid 1 (TRPV1)
is a nonselective cation channel and a molecular integrator of
noxious stimuli. TRPV1 activation confers cardiac protection
against ischemia/reperfusion (I/R) injury. The present study
aimed to investigate whether the cardioprotective effects of
TRPV1 were associated with the inhibition of apoptosis via
the phosphatidylinositol 3‑kinase (PI3K)/protein kinase B
(Akt) and extracellular signal‑regulated protein kinase 1/2
(ERK1/2) signaling pathways. Briefly, the hearts of TRPV1
knockout (TRPV1‑/‑) or wild‑type (WT) mice were isolated and
subjected to 30 min of ischemia followed by 60 min of reperfusion in a Langendorff apparatus in the presence or absence
of the PI3K inhibitor, LY294002. At the end of reperfusion,
infarct size was measured using 2,3,5‑triphenyltetrazolium
chloride staining and myocardial apoptosis was assessed
by terminal deoxynucleotidyl transferase‑mediated dUTP
nick‑end labeling (TUNEL) staining. The expression levels of
B‑cell lymphoma 2 (Bcl‑2), Bcl‑2‑associated X protein (Bax),
and phosphorylated Akt and ERK1/2 were determined by
western blot analysis. There was a significant increase in the
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extent of infarction and the percentage of TUNEL‑positive
cells, and a decrease in the Bcl‑2/Bax ratio, and Akt and
ERK1/2 phosphorylation in TRPV1‑/‑ hearts. In addition, treatment with LY294002 increased infarct size and the percentage
of TUNEL‑positive cells, and reduced Bcl‑2/Bax expression
and Akt phosphorylation in WT hearts, but not in TRPV1‑/‑
hearts, following I/R. Taken together, these data suggested that
TRPV1 serves a protective role against myocardial apoptosis
during I/R via the PI3K/Akt signaling pathway. In conclusion,
activating TRPV1 may be considered a potential approach to
protect the heart against I/R injury.
Introduction
Ischemic heart disease is a leading cause of morbidity and
mortality (1,2). Reperfusion of coronary arteries in response to
thrombolytic treatment or percutaneous coronary intervention
is crucial for reducing ischemia‑induced heart damage (3‑5).
However, reperfusion may induce additional myocardial
injury, including cardiomyocyte death and loss of cardiac
function; this is known as myocardial ischemia/reperfusion
(I/R) injury (6‑8). The cellular mechanisms underlying I/R
injury remain to be completely elucidated. Increasing evidence
has suggested that ischemia initiates myocardial apoptosis,
which is amplified by reperfusion, thus contributing to cardiac
cell death (9,10). Conversely, suppressing apoptotic processes
can minimize I/R‑induced cardiac damage (11).
Transient receptor potential vanilloid 1 (TRPV1) is a
ligand‑gated nonselective cation channel, which is primarily
expressed in sensory nerves that innervate cardiovascular
tissues, including the heart and blood vessels (12,13). TRPV1
has been considered to act as a molecular integrator of
numerous chemical and physical mediators, including noxious
heat, low pH, capsaicin and lipid metabolites (14‑16). TRPV1
expressed in the cardiac sensory nerves, which conduct angina
pain signals (17,18), may function as a molecular sensor for
the detection of tissue ischemia and the modulation of cardiac
function (12). Pharmacological studies have suggested that
activation of TRPV1 with exogenous agonists protects the
heart from I/R injury (19,20), whereas TRPV1 gene deletion
may impair cardiac recovery following I/R (21). Furthermore,
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activation of TRPV1 inhibits hypoxia/reoxygenation‑induced
apoptosis in rat hippocampal neurons via activation of the
phosphatidylinositol 3‑kinase/protein kinase B (PI3K/Akt)
and extracellular signal‑regulated protein kinase 1/2 (ERK1/2)
signaling pathways (22), which are key regulators of cell
growth and survival (23,24). During I/R, both signaling pathways are activated and confer cardioprotective effects through
the recruitment of downstream anti‑apoptotic molecules (25);
however, the role of TRPV1 in myocardial apoptosis in response
to I/R injury remains to be fully characterized. Furthermore,
it is currently unknown whether the PI3K/Akt and ERK1/2
signaling pathways are involved in TRPV1‑mediated myocardial apoptosis in I/R. The present study aimed to determine
the effects of TRPV1 activation on myocardial apoptosis in
response to I/R injury and explored the downstream signaling
mechanism of TRPV1 activation.
Materials and methods
Animals and reagents. Male TRPV1 knockout (TRPV1‑/‑) and
wild‑type (WT) C57BL/6J mice (n=54 each; weight, 25‑30 g;
age, 10‑12 weeks) were provided by the Experimental Animal
Center of Chongqing Medical University (Chongqing, China)
and were maintained under specific pathogen‑free conditions
(temperature, 22˚C; humidity, 60%), with a 12‑h light/dark
cycle and with free access to food and water. All surgical
procedures performed on mice were conducted under sodium
pentobarbital anesthesia [50 mg/kg, intraperitoneal (IP) injection], and all efforts were made to minimize their suffering.
The present study was approved by the Ethics Committee
of Chongqing Medical University. The mice were treated in
accordance with the recommendations listed in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health (NIH) (26).
LY294002 (a PI3K inhibitor) and 2,3,5‑triphenyl tetrazolium chloride (TTC) were purchased from Sigma‑Aldrich
(Merck KGaA, Darmstadt, Germany); antibodies against phosphorylated (p)‑Akt (Ser473; cat. no. 9271), Akt (cat. no. 9272),
p‑ERK1/2 (Thr202/Thr204; cat. no. 4370), ERK1/2
(cat. no. 9102), B‑cell lymphoma‑2 (Bcl‑2; cat. no. 2870)
and Bcl‑2‑associated X protein (Bax; cat. no. 14796) were
purchased from Cell Signaling Technology, Inc. (Danvers,
MA, USA). Anti‑GAPDH antibody (cat. no. AG019) and the
bicinchoninic acid (BCA) protein assay kit were purchased
from Beyotime Institute of Biotechnology (Haimen, China).
The terminal deoxynucleotidyl transferase‑mediated dUTP
nick‑end labeling (TUNEL) reaction mixture was purchased
from Roche Diagnostics (Laval, QC, Canada).
Langendorff heart preparation. Mice were treated with
heparin (500 U/kg, IP) and anesthetized with pentobarbital
sodium (50 mg/kg, IP) prior to thoracotomy. The hearts were
rapidly excised, placed into ice‑cold Krebs‑Henseleit (K‑H)
buffer (composition in mM: NaCl 118, KCl 4.7, MgSO4 1.2,
KH 2PO 4 1.2, CaCl 2 2.5, NaHCO3 25, Na‑EDTA 0.5 and
glucose 11) and perfused in a Langendorff apparatus within
2 min under a constant pressure of 80 mmHg. The perfusion
fluid was oxygenated with a mixture of 95% O2 and 5% CO2,
and was maintained at pH 7.4. In addition, temperature of the
K‑H buffer was maintained at 37˚C throughout the experi-
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ment. A fluid‑filled balloon connected to a pressure transducer
was inserted into the left ventricle (LV) via the mitral valve to
monitor LV pressure. The volume of the balloon was adjusted
to maintain a stable LV end‑diastolic pressure of 5‑8 mmHg
during initial equilibration.
Experimental protocol. The isolated mouse hearts were
randomly divided into the following six groups (n=9/group):
i) WT Sham group; ii) TRPV1‑/‑ Sham group; iii) WT I/R
group; iv) TRPV1‑/‑ I/R group; v) WT I/R + LY294002 group;
and vi) TRPV1‑/‑ I/R + LY294002 group. To induce I/R, the
perfused hearts were stabilized for 30 min and subjected to
global normothermic (37˚C) ischemia (no flow) for 30 min,
followed by 60 min of reperfusion. Conversely, hearts in the
sham groups were perfused with K‑H solution continuously
until the end of the experiment. Hearts in the LY294002 treatment group were perfused for 10 min with LY294002 (50 µM)
in K‑H buffer prior to induction of global ischemia, the hearts
were then subjected to global ischemia followed by reperfusion without LY294002. LY294002 was initially dissolved
in dimethyl sulfoxide and then in K‑H buffer to reach a final
concentration of 50 µM. The concentration of LY294002 used
in the present study has been reported to specifically abolish
PI3K activity and inhibit Akt phosphorylation, but not the
phosphorylation of other protein kinases, including phosphatidylinositol 4‑kinase, protein kinase C, mitogen‑activated
protein kinase or c‑Src (27). The experimental protocol is
presented in Fig. 1.
Determination of myocardial infarct size. At the end of
reperfusion, the hearts were frozen at ‑20˚C for 15 min and
cut into five pieces along the longitudinal heart axis. Heart
sections were incubated for 10 min in 1% TTC at 37˚C in the
dark. Subsequently, the sections were soaked in 4% paraformaldehyde in phosphate buffer overnight at 4˚C to enhance
the contrast of the stain. Viable myocardium exhibited red
staining, whereas the infarcted area exhibited white staining.
Each image was digitally photographed and the infarct size
was analyzed using ImageJ software version 1.49v (NIH,
Bethesda, MD, USA). The infarct size was expressed as a
percentage of the total area of the heart.
Measurement of myocardial cell apoptosis. For tissue TUNEL
staining, the heart samples were fixed in 4% paraformaldehyde
at 25˚C for 24 h, embedded in paraffin and cut into transverse
sections (5 µm). Myocardial apoptosis was assessed using a
TUNEL staining kit according to the manufacturer's protocol.
The numbers of TUNEL‑positive myocyte nuclei and total
myocyte nuclei were counted in 10 different fields for each
stained section at high magnification (objective, x400). The
number of TUNEL‑positive nuclei (brown staining) was
calculated using ImageJ software (NIH) according to the
following formula: Percentage of TUNEL‑positive myocyte
nuclei = TUNEL‑positive myocyte nuclei/total myocyte
nuclei x 100%.
Western blot analysis. Total proteins were extracted from
mouse heart tissues and protein concentrations were assessed
using a BCA protein assay kit. The mouse heart tissues were
homogenized using radioimmunoprecipitation lysis buffer
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Figure 1. Experimental protocol. Isolated hearts from WT and TRPV1‑/‑ mice were subjected to 30 min no‑flow global ischemia followed by 60 min of
reperfusion. The sham‑operated group underwent time‑matched perfusion without ischemia. LY (50 µM) was perfused for 10 min prior to ischemia. I/R,
ischemia/reperfusion; LY, LY294002; TRPV1-/-, transient receptor potential vanilloid 1 knockout; WT, wild‑type.

(RIPA; Beyotime Institue of Biotechnology) and then centrifuged at 4˚C. Equal amounts of protein (4 µg/µl) were separated
by 10‑12% SDS‑PAGE and were transferred onto polyvinylidene fluoride (PVDF) membranes (Bio‑Rad Laboratories,
Inc., Hercules, CA, USA). The PVDF membranes were
blocked in 5% non-fat milk in Tris-buffered saline containing
0.05% Tween-20 for 2 h at room temperature, and were then
incubated overnight at 4˚C with primary antibodies against
GAPDH (1:1,000 dilution), p‑Akt (Ser473) (1:1,000 dilution),
Akt (1:1,000 dilution), p‑ERK1/2 (Thr202/Thr204) (1:2,000
dilution), ERK1/2 (1:1,000 dilution), Bcl‑2 (1:1,000 dilution)
and Bax (1:1,000 dilution). Subsequently, the membranes were
incubated with horseradish peroxidase‑conjugated secondary
antibodies (1:5,000 dilution; ZB-5305; Beijing Zhongshan
Golden Bridge Biotechnology Co., Beijing, China) for 2 h at
room temperature. The immunoreactive proteins were visualized using an enhanced chemiluminescence detection system
(Pierce; Thermo Fisher Scientific Inc., Waltham, MA, USA).
The band density was analyzed by ImageJ software (NIH).
Statistical analysis. SPSS 17.0 statistical software (SPSS, Inc.,
Chicago, IL, USA) was used for all statistical analyses. Data
are expressed as the means ± standard deviation. Significance
was determined using either an unpaired Student's t‑test
(differences in TUNEL-positive cells and infarct size in
TRPV1-/- hearts compared with in WT hearts) or one‑way
analysis of variance followed by the Tukey‑Kramer multiple
comparison test. P<0.05 was considered to indicate a statistically significant difference.
Results
Myocardial apoptosis is increased in TRPV1‑/‑ hearts following
I/R. To investigate the role of TRPV1 in apoptosis, WT and
TRPV1‑/‑ hearts were subjected to I/R, and myocardial apoptosis
was detected using TUNEL staining (Fig. 2). The percentage
of TUNEL‑positive cardiomyocytes was markedly increased

in the TRPV1‑/‑ and WT hearts following I/R compared with
in the respective sham control groups (P<0.01). Furthermore,
the percentage of TUNEL‑positive cardiomyocytes in TRPV1‑/‑
hearts subjected to I/R was significantly greater than in WT
hearts (25.10+1.03 vs. 18.20+2.79%; P<0.01). In addition, treatment with the PI3K inhibitor LY294002 prior to I/R, increased
myocardial apoptosis in WT (P<0.01) but not in TRPV1‑/‑ hearts
(P>0.05) (Fig. 2).
Infarct size is larger in TRPV1‑/‑ hearts following I/R. Myocardial
infarct size was assessed using TTC staining (Fig. 3). Myocardial
infarct size was markedly increased in the TRPV1‑/‑ and WT
groups following I/R compared with in the corresponding
sham groups (P<0.01) (data not shown). Notably, infarct size in
TRPV1‑/‑ hearts was markedly increased compared with in the
WT hearts (49.58+4.83 vs. 26.32+4.57%; P<0.01). In addition,
treatment with LY294002 significantly increased infarct size
in WT (P<0.01) but not in TRPV1‑/‑ hearts (P>0.05) (Fig. 3).
PI3K/Akt signaling is involved in the anti‑apoptotic effects of
TRPV1. The PI3K/Akt and ERK1/2 survival signaling pathways
serve key roles in protecting cardiomyocytes from apoptosis
during I/R injury. To determine the downstream signaling
pathway associated with the effects of TRPV1, Akt and ERK1/2
phosphorylation was detected in heart samples exposed to
I/R (Fig. 4). Myocardial I/R significantly increased p‑Akt and
p‑ERK1/2 expression in TRPV1‑/‑ and WT hearts (P<0.05),
without any significant changes in total ERK1/2 and Akt protein
levels. The ratios of p‑AKT/AKT and p‑ERK1/2/ERK1/2 were
significantly higher following I/R in WT hearts compared with
in TRPV1‑/‑ hearts (P<0.01); however, these ratios were decreased
following LY294002 treatment (P<0.01) (Fig. 4). These results
suggested that the PI3K/Akt signaling pathway may be involved
in the beneficial effects of TRPV1 during I/R injury.
TRPV1 activation increases Bcl‑2/Bax ratio by activating
the PI3K‑Akt signaling pathway. To further examine the
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Figure 2. I/R injury induced myocardial apoptosis, as determined by TUNEL staining. (A) Representative photomicrographs of TUNEL staining (scale bars,
50 µm). (B) Bar graph showing the quantified results of TUNEL staining analysis. TUNEL‑positive cells are shown at x400 magnification. Black arrows
indicate TUNEL‑positive cells. Data are presented as the means ± standard deviation of three independent experiments. *P<0.01 vs. the WT Sham group;
**
P<0.01 vs. the TRPV1‑/‑ Sham group; #P<0.01 vs. the WT I/R group. I/R, ischemia/reperfusion; LY, LY294002; TRPV1-/-, transient receptor potential vanilloid 1 knockout; TUNEL, terminal deoxynucleotidyl transferase‑mediated dUTP nick‑end labeling; WT, wild‑type.

mechanism of apoptosis, the protein expression levels of Bax
and Bcl‑2 were determined (Fig. 5). Bcl‑2 and Bax have major
roles in determining cell survival or death in response to apoptotic stimuli (28,29). The present study demonstrated that I/R
resulted in a significant decrease in Bcl‑2/Bax protein ratio
compared with in the sham group in TRPV1‑/‑ and WT hearts
(P<0.05). In addition, the ratio of Bcl‑2/Bax was lower in the
of TRPV1‑/‑ hearts compared with in WT hearts following I/R
(P<0.01). Furthermore, treatment with LY294002 markedly
decreased Bcl‑2/Bax ratio in WT hearts (P<0.01) but not in
TRPV1‑/‑ hearts (Fig. 5).
Discussion

Figure 3. Infarct size, as measured by TTC staining following 30 min of
global ischaemia and 60 min of reperfusion. Upper panels are the representative cross‑sections of TTC‑stained hearts. White staining indicates the
infarcted region, and red staining indicates viable myocardium. Data are presented as the means ± standard deviation of three independent experiments.
*
P<0.01 vs. the WT I/R group. I/R, ischemia/reperfusion; LY, LY294002;
TRPV1-/-, transient receptor potential vanilloid 1 knockout; TTC, I/R, ischemia/reperfusion; WT, wild‑type.

The present study demonstrated that TRPV1 gene knockdown significantly increased myocardial apoptosis and
infarction during I/R. In addition, treatment with the PI3K
inhibitor LY294002 increased infarct size and number of
TUNEL‑positive cardiomyocytes in WT but not in TRPV1‑/‑
hearts. These results indicated that TRPV1 may protect the
heart against I/R injury, possibly through its anti‑apoptotic
effects via activating the PI3K/Akt signaling pathway.
The importance of the TRPV1 channel in regulating
heart function has recently been highlighted. TRPV1 can
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Figure 4. Phosphorylation of Akt and ERK1/2 following I/R. (A) Protein expression levels of p‑Akt and total Akt, and (B) p‑ERK1/2 and total ERK1/2 were
assessed by western blotting with specific antibodies. Protein signals were semi‑quantified by densitometry, and relative levels are presented in graphs. Data
are presented as the means ± standard deviation of three independent experiments. *P<0.05 vs. the WT Sham group; **P<0.05 vs. the TRPV1‑/‑ Sham group;
#
P<0.01 vs. the WT I/R group. Akt, protein kinase B; ERK1/2, extracellular signal‑regulated protein kinase 1/2; I/R, ischemia/reperfusion; LY, LY294002; p-,
phosphorylated; TRPV1-/-, transient receptor potential vanilloid 1 knockout; WT, wild‑type.

Figure 5. Bcl‑2/Bax ratio following I/R. Bcl‑2 and Bax protein levels were
determined by western blot analysis. Data are presented as the means ± standard deviation of three independent experiments. *P<0.05 vs. the WT Sham
group; **P<0.05 vs. the TRPV1‑/‑ Sham group; #P<0.01 vs. the WT I/R group.
Bax, Bcl‑2‑associated X protein; Bcl‑2, B‑cell lymphoma 2; I/R, ischemia/reperfusion; LY, LY294002; p-, phosphorylated; TRPV1-/-, transient
receptor potential vanilloid 1 knockout; WT, wild‑type.

be activated by numerous metabolites that are accumulated
during myocardial ischemia (12). Prior induction of TRPV1
may confer a benefit to the myocardium against further severe
damage. This concept is supported by evidence that suggests
that short episodes of sub‑lethal ischemia may induce ischemic preconditioning, and that TRPV1 knockout abrogates the

effects of ischemic preconditioning (30). In addition, TRPV1
activation promotes recovery of cardiac systolic/diastolic
function during I/R (21). Apoptosis is a type of programmed
cell death, which significantly contributes to myocardial I/R
injury (9,10); therefore, inhibition of myocardial cell apoptosis
may prevent cell loss and attenuate cardiac injury during
myocardial I/R (11). Apoptosis‑associated proteins, including
Bcl‑2 and Bax serve pivotal roles in apoptosis (28,29).
In particular, apoptosis is regulated by the ratio of Bcl‑2
and Bax protein expression (31,32). Previous studies have
indicated that TRPV1 is involved in the regulation of apoptosis (22,33‑35). Capsaicin has been reported to significantly
reduce reperfusion‑induced liver injury by reducing apoptosis
due to activation of TRPV1 (34). Therefore, the present study
investigated the role of TRPV1 in myocardial apoptosis during
I/R. The results demonstrated that the Bcl‑2/Bax ratio was
significantly reduced in TRPV1‑/‑ compared with WT hearts
following I/R. Furthermore, I/R increased the percentage
of TUNEL‑positive cells and infarct size in TRPV1‑/‑ hearts
compared with in WT hearts. These findings suggested that
TRPV1 activation protects cardiomyocytes from I/R injury
by suppressing myocardial apoptosis. Although cardiac function was not assessed in the present study, our previous study
demonstrated that TRPV1 deficiency results in increased
mortality, aggravated inflammatory response, enhanced
cardiac fibrosis and exaggerated progression of LV remodeling 7 days after myocardial infarction (36). However, further
studies are required to investigate the role of TRPV1 in regulating cardiac function following I/R in vivo.
Previous studies have revealed that capsaicin activates
the PI3K/Akt and ERK1/2 pathways in dorsal root ganglion
neurons (37) and human HepG2 cells (38) through activation
of the capsaicin receptor TRPV1. The PI3K/Akt and ERK1/2
signaling pathways, when specifically activated at the time of
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myocardial reperfusion, may inhibit cardiomyocyte apoptosis
and attenuate I/R injury through targeting downstream molecules, including Bcl‑2 and Bax (39,40). Therefore, the present
study investigated the role of TRPV1 in phosphorylation of Akt
and ERK1/2 in hearts subjected to I/R. The results indicated that
the ratios of p‑AKT/AKT and p‑ERK1/2/ERK1/2 were upregulated in TRPV1‑/‑ and WT hearts following I/R compared with
in the sham groups. In addition, the ratios of p‑AKT/AKT and
p‑ERK1/2/ERK1/2 were lower in TRPV1‑/‑ hearts compared
with in WT hearts. Notably, treatment with LY294002 decreased
Bcl‑2/Bax ratio, and increased infarct size and TUNEL‑positive
cardiomyocytes in WT but not in TRPV1‑/‑ hearts. These results
suggested that TRPV1 may inhibit I/R‑induced cardiomyocyte
apoptosis via PI3K/Akt activation. In addition, treatment with
LY294002 significantly inhibited p‑ERK1/2 levels in WT but not
TRPV1‑/‑ hearts following I/R. Previous evidence has suggested
that PI3K inhibition suppresses ERK1/2 activation induced by
capsaicin and nerve growth factor in primary sensory dorsal
root ganglion neurons (41), which is supported by the present
study. However, in a previous study, PI3K has been reported
to inhibit, rather than increase, ERK1/2 activation (42). It has
been suggested that the ability of PI3K inhibitors to suppress
ERK1/2 activation depends on cell type, the type of stimuli and
the strength of signals (43,44). In the present study, PI3K inhibition decreased I/R‑induced ERK1/2 activation in WT mice, thus
suggesting that ERK1/2 activation is PI3K‑dependent. Further
studies are required to explore the precise role of the ERK1/2
signaling pathway in TRPV1‑induced cardiac protection.
As an ex vivo model, the Langendorff preparation has its
limitations. For example, the isolated and perfused heart is
denervated and its performance is not regulated by neurohumoral factors. In addition, crystalloid‑perfused hearts are prone
to tissue edema, which has a negative impact on cardiac function, particularly in I/R study protocols >2 h, which is not the
case in the present study. However, the preparation is simple,
reproducible and enables the study of the heart without other
organ systems, which may confound physiological assessment.
Due to these advantages, the Langendorff model has been used
for >100 years to generate insightful data.
In conclusion, the present study demonstrated that TRPV1
may exert anti‑apoptotic effects against myocardial I/R injury
via PI3K/Akt signaling activation in isolated mouse hearts.
These data suggested that TRPV1 may be considered a potential target for pharmacological intervention to reduce cardiac
damage and improve clinical outcomes following cardiac I/R.
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